Table 6. Biochemical data of the subjects (safety set).
| Placebo Group (n = 64) | Bio-Germanium Group (n = 66) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Follow-up1 | Δ | Baseline | Follow-up | Δ | P | |
| White Blood Cell (×103/μL) | 5.53 ± 1.01 | 5.47 ± 1.39 | -0.05 ± 1.33 | 5.38 ± 1.06 | 5.17 ± 1.15 | -0.21 ± 1.22 | 0.483 |
| Red Blood Cell (×106/μL) | 4.62 ± 0.66 | 4.72 ± 0.69 | 0.10 ± 0.85 | 4.62 ± 0.58 | 4.78 ± 0.77 | 0.15 ± 0.93 | 0.733 |
| Hemoglobin (g/dL) | 13.50 ± 1.36 | 13.70 ± 1.89 | 0.20 ± 1.72 | 13.69 ± 1.84 | 13.99 ± 2.25 | 0.30 ± 2.59 | 0.805 |
| Hematocrit (%) | 41.94 ± 6.13 | 42.63 ± 6.30 | 0.70 ± 7.86 | 41.96 ± 5.47 | 43.33 ± 7.47 | 1.37 ± 8.61 | 0.647 |
| Platelet (×103/mm3) | 251.81 ± 63.92 | 225.79 ± 52.22 | -25.38 ± 52.96 | 239.17 ± 57.83 | 220.68 ± 50.76 | -18.48 ± 62.81 | 0.502 |
| Lymphocyte (×103/mm3) | 1.96 ± 0.47 | 1.90 ± 0.51 | -0.05 ± 0.41 | 1.97 ± 0.54 | 1.86 ± 0.48 | -0.11 ± 0.36 | 0.413 |
| Monocyte (×103/mm3) | 0.18 ± 0.07 | 0.17 ± 0.08 | -0.01 ± 0.09 | 0.19 ± 0.09 | 0.17 ± 0.07 | -0.02 ± 0.09 | 0.416 |
| AST (IU/L) | 23.52 ± 7.95 | 21.38 ± 6.96 | -1.57 ± 3.84 | 22.59 ± 6.52 | 21.12 ± 5.60 | -1.47 ± 4.17 | 0.886 |
| ALT (IU/L) | 20.31 ± 13.97 | 18.86 ± 13.01 | -0.70 ± 6.37 | 19.68 ± 9.09 | 18.48 ± 7.69 | -1.20 ± 4.68 | 0.615 |
| Total Protein (g/dL) | 7.34 ± 0.35 | 7.50 ± 0.33 | 0.17 ± 0.33 | 7.32 ± 0.36 | 7.48 ± 0.35 | 0.16 ± 0.31 | 0.913 |
| Glucose (mg/dL) | 90.89 ± 10.64 | 92.49 ± 11.67 | 1.68 ± 8.02 | 88.61 ± 10.18 | 91.82 ± 10.14 | 3.21 ± 7.00 | 0.250 |
| Total Cholesterol (mg/dL) | 194.86 ± 39.98 | 205.95 ± 42.67 | 10.13 ± 22.85 | 194.70 ± 38.31 | 201.68 ± 38.36 | 6.98 ± 18.24 | 0.389 |
| BUN (mg/dL) | 14.48 ± 3.78 | 14.44 ± 3.62 | -0.08 ± 3.30 | 14.53 ± 0.18 | 14.56 ± 3.44 | 0.03 ± 2.87 | 0.841 |
| Creatinine (mg/dL) | 0.69 ± 0.14 | 0.66 ± 0.12 | -0.03 ± 0.09 | 0.71 ± 0.16 | 0.69 ± 0.16 | -0.02 ± 0.10 | 0.576 |
| Uric acid (mg/dL) | 4.57 ± 1.20 | 4.61 ± 1.08 | 0.03 ± 0.70 | 4.48 ± 1.03 | 4.58 ± 1.09 | 0.10 ± 0.65 | 0.575 |
| Ca (mg/dL) | 9.36 ± 0.37 | 9.40 ± 0.33 | 0.03 ± 0.39 | 9.38 ± 0.35 | 9.39 ± 0.28 | 0.01 ± 0.33 | 0.778 |
| P (mg/dL) | 3.80 ± 0.47 | 3.84 ± 0.49 | 0.03 ± 0.45 | 3.77 ± 0.44 | 3.86 ± 0.43 | 0.09 ± 0.33 | 0.375 |
The data represent the mean ± standard deviation.
Δ represents the change from baseline at follow-up.
P-values were derived from an independent t-test for Δ between groups.
1 Safety set analysis of the placebo group at follow-up consisted of 63 participants, excluding one subject’s voluntary dropout.